369 related articles for article (PubMed ID: 32645631)
1. Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting.
d'Alessandro M; Perillo F; Metella Refini R; Bergantini L; Bellisai F; Selvi E; Cameli P; Manganelli S; Conticini E; Cantarini L; Sestini P; Frediani B; Bargagli E
Int Immunopharmacol; 2020 Sep; 86():106748. PubMed ID: 32645631
[TBL] [Abstract][Full Text] [Related]
2. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
Smolen JS; Xie L; Jia B; Taylor PC; Burmester G; Tanaka Y; Elias A; Cardoso A; Ortmann R; Walls C; Dougados M
Rheumatology (Oxford); 2021 May; 60(5):2256-2266. PubMed ID: 33200220
[TBL] [Abstract][Full Text] [Related]
5. The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis: Preliminarily data from single center-based observational study for 24 weeks.
Kim SK; Jung UH; Kim JW; Choe JY
Medicine (Baltimore); 2021 Jul; 100(30):e26739. PubMed ID: 34397713
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
7. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
[TBL] [Abstract][Full Text] [Related]
8. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
[TBL] [Abstract][Full Text] [Related]
9. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.
van de Laar CJ; Oude Voshaar MAH; Ten Klooster P; Tedjo DI; Bos R; Jansen T; Willemze A; Versteeg GA; Goekoop-Ruiterman YPM; Kroot EJ; van de Laar M
RMD Open; 2024 May; 10(2):. PubMed ID: 38816210
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
Amrhein J; Drynda S; Schlatt L; Karst U; Lohmann CH; Ciarimboli G; Bertrand J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927842
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of baricitinib on periodontal inflammation in patients with rheumatoid arthritis.
Ancuța C; Pomîrleanu C; Mihailov C; Chirieac R; Ancuța E; Iordache C; Bran C; Țănculescu O
Joint Bone Spine; 2020 May; 87(3):235-239. PubMed ID: 31962162
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report.
Valor-Méndez L; Voskens C; Rech J; Kleyer A; Schett G
Rheumatology (Oxford); 2021 Apr; 60(4):e122-e123. PubMed ID: 33141876
[No Abstract] [Full Text] [Related]
15. Massive nodulous lesions on hands and feet in a RA patient and improvement under baricitinib treatment.
Valor-Méndez L; Hagen M; Kleyer A; Manger B; Schett G
RMD Open; 2020 Nov; 6(3):. PubMed ID: 33214327
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of baricitinib in rheumatoid arthritis: a monocentric, longitudinal, real-life experience.
Spinelli FR; Ceccarelli F; Garufi C; Duca I; Mancuso S; Cipriano E; Dell'Unto E; Alessandri C; Di Franco M; Perricone C; Priori R; Riccieri V; Scrivo R; Sili Scavalli A; Truglia S; Valesini G; Conti F
Clin Exp Rheumatol; 2021; 39(3):525-531. PubMed ID: 33337992
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
Asai S; Takahashi N; Kobayakawa T; Kaneko A; Watanabe T; Kato T; Nishiume T; Ishikawa H; Yoshioka Y; Kanayama Y; Watanabe T; Hirano Y; Hanabayashi M; Yabe Y; Yokota Y; Suzuki M; Terabe K; Ishiguro N; Imagama S; Kojima T
Clin Rheumatol; 2021 Aug; 40(8):3143-3151. PubMed ID: 34136969
[TBL] [Abstract][Full Text] [Related]
19. The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
Thudium CS; Bay-Jensen AC; Cahya S; Dow ER; Karsdal MA; Koch AE; Zhang W; Benschop RJ
Arthritis Res Ther; 2020 Oct; 22(1):235. PubMed ID: 33046136
[TBL] [Abstract][Full Text] [Related]
20. Resolution of exacerbated rheumatoid arthritis-associated interstitial lung disease under baricitinib treatment.
Komai T; Sawada T; Tsuchiya H; Harada H; Shoda H; Fujio K
Scand J Rheumatol; 2024 Mar; 53(2):146-148. PubMed ID: 38031721
[No Abstract] [Full Text] [Related]
[Next] [New Search]
